COMPANY PROFILE

Versanis Bio

This company is developing a new approach to obesity treatment that could have a significant and lasting impact on patients with this condition

New York City, United StatesFounded 2021Biotech & Life Sciences

Valuation $1–2.5B Last recorded · 2023

Headcount <100 Current team size

Total funding $50–100M Disclosed equity funding

Unlock exact values

About Versanis Bio

Versanis Bio is a biotechnology company focused on developing novel therapeutics for obesity and cardiometabolic diseases. The company's lead candidate, bimagrumab, is a first-in-class monoclonal antibody that targets activin type II receptors, directly impacting fat and muscle tissue. This approach aims to provide significant and lasting benefits for patients suffering from obesity and related cardiometabolic conditions. Versanis Bio operates in the healthcare and pharmaceutical market, primarily serving patients and healthcare providers. The company's business model revolves around the research, development, and commercialization of its therapeutic candidates. Revenue is generated through the sale of these therapeutics, as well as potential partnerships and licensing agreements with other pharmaceutical companies.

MoreLess Source: Dealroom company data

At a glance

Status: Acquired
Founded: 2021
Headquarters: New York City, United States
Employees: 21
Open positions: None listed
Dealroom signal: 26.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Became $1B as Subsidiary, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

2 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
ACQUISITIONOther financing	Jul 2023	$1.9B	$1.9B	Eli Lilly	↗
SERIES AOther financing	Aug 2021	$70M	$280M	Medicxi · Aditum Bio · Atlas Venture	—

Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Versanis Bio website traffic

Latest recorded traffic for Versanis Bio is 1K monthly website visits, up 69.5% over the last three months. Versanis Bio's team grew 0% over the past year.

Latest monthly visits1K 3-month web change+69.5% 1-year team growth0%

Monthly website visitsNov 2022–Aug 2024

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
SSSecondWave SystemsDeveloping a novel, ultrasound-based wearable neuromodulation platform	Minneapolis, United States	Operational	19	$17M	$28M
FUFunPepFunPep is an Industry-university collaboration bioventure company	Ibaraki, Japan	Operational
AIArterial Health InternationalProvides clinical diagnostic tests for a comprehensive evaluation of cardiovascular disease risk factors	Atlanta, United States	Operational
LYLysoclearPremium laboratory research services for biotechnology and pharmaceutical companies, specializing in ocular toxicology and structural biology	Lafayette, United States	Operational
TBTAGCyx BiotechnologiesCreating candidate compounds for high-performance nucleic acid drugs with high affinity and specificity for target molecules using our proprietary nucleic acid basic technology	Tokyo, Japan	Acquired
ANAmygdala NeuroscienceAmygdala's mission is to address the growing unmet need associated with substance use disorder by discovering, developing and commercializing safe and effective pharmacotherapies to treat and prevent addiction	Palo Alto, United States	Operational
ATAnHeart TherapeuticsPrecision medicine biopharmaceutical company leveraging expertise in clinical research and development and product registration focusing initially on oncology products	Huangpu, China	Acquired
CBContraria BiotechDevelops innovative, cost-effective therapeutic and prophylactic drugs to combat global health challenges like antibiotic resistance, emerging diseases, and pandemics	Siena, Italy	Operational